319 related articles for article (PubMed ID: 14705962)
41. Dihydropyrimidine dehydrogenase deficiency presenting with psychomotor retardation in the first Polish patient.
Mazur A; Figurski S; Płoskoń A; Meijer J; Zoetekouw L; Watróbska S; Sykut-Cegielska J; Gradowska W; van Kuilenburg AB
Acta Biochim Pol; 2008; 55(4):787-90. PubMed ID: 19081848
[TBL] [Abstract][Full Text] [Related]
42. Dihydropyrimidine dehydrogenase deficiency presenting at birth.
Al-Sanna'a NA; Van Kuilenburg AB; Atrak TM; Abdul-Jabbar MA; Van Gennip AH
J Inherit Metab Dis; 2005; 28(5):793-6. PubMed ID: 16151913
[TBL] [Abstract][Full Text] [Related]
43. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer.
Nakayama Y; Inoue Y; Nagashima N; Katsuki T; Matsumoto K; Kadowaki K; Shibao K; Tsurudome Y; Hirata K; Sako T; Nagata N; Itoh H
Anticancer Res; 2005; 25(6A):3755-61. PubMed ID: 16302736
[TBL] [Abstract][Full Text] [Related]
44. Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients.
Furuhata T; Kawakami M; Okita K; Kimura Y; Kihara C; Tsuruma T; Ohmura T; Yamaguchi K; Hata F; Katsuramaki T; Sasaki K; Hirata K
J Exp Clin Cancer Res; 2006 Mar; 25(1):79-82. PubMed ID: 16761622
[TBL] [Abstract][Full Text] [Related]
45. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
46. [Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences].
Barrat-Petit MA; Naulin-Ifi C; Mahler P; Milano G
Pathol Biol (Paris); 2005 Jun; 53(5):261-4. PubMed ID: 15939134
[TBL] [Abstract][Full Text] [Related]
47. Diagnosis of dihydropyrimidine dehydrogenase deficiency in a neonate with thymine-uraciluria.
Au KM; Lai CK; Yuen YP; Shek CC; Lam CW; Chan AY
Hong Kong Med J; 2003 Apr; 9(2):130-2. PubMed ID: 12668826
[TBL] [Abstract][Full Text] [Related]
48. Dihydropyrimidine dehydrogenase deficiency in a Hutterite newborn.
Adolph KJ; Fung E; McLeod DR; Morgan K; Snyder FF
Adv Exp Med Biol; 1991; 309B():311-4. PubMed ID: 1781388
[No Abstract] [Full Text] [Related]
49. Urinary excretion of beta-aminoisobutyric acid in hematological diseases.
Enkhjargal Ts; Tserennadmid Ch
Rinsho Byori; 2004 Jan; 52(1):17-21. PubMed ID: 14968554
[TBL] [Abstract][Full Text] [Related]
50. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy.
Milano G; Etienne MC
Pharmacogenetics; 1994 Dec; 4(6):301-6. PubMed ID: 7704035
[No Abstract] [Full Text] [Related]
51. Dihydropyrimidine dehydrogenase deficiency--a further case.
Wilcken B; Hammond J; Berger R; Wise G; James C
J Inherit Metab Dis; 1985; 8 Suppl 2():115-6. PubMed ID: 3930855
[No Abstract] [Full Text] [Related]
52. Beta-amino acids: mammalian metabolism and utility as alpha-amino acid analogues.
Griffith OW
Annu Rev Biochem; 1986; 55():855-78. PubMed ID: 3090932
[No Abstract] [Full Text] [Related]
53. Pyrimidine metabolism in man.
Smith LH
N Engl J Med; 1973 Apr; 288(15):764-71. PubMed ID: 4143960
[No Abstract] [Full Text] [Related]
54. 5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients.
Reerink O; Mulder NH; Szabo BG; Hospers GA
Anticancer Res; 2004; 24(3b):1969-71. PubMed ID: 15274386
[TBL] [Abstract][Full Text] [Related]
55. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
Coriat R; Chaussade S
Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
[TBL] [Abstract][Full Text] [Related]
56. Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine.
Sumi S; Kidouchi K; Kondou M; Hayashi K; Dobashi K; Kouwaki M; Togari H; Wada Y
Int J Mol Med; 1998 Oct; 2(4):477-82. PubMed ID: 9857238
[TBL] [Abstract][Full Text] [Related]
57. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
58. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
[TBL] [Abstract][Full Text] [Related]
59. Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions.
van den Wildenberg SAH; Streng AS; van den Broek R; Broeren MAC; Deenen MJ; van Dongen JLJ; Hanrath MA; Lapré C; Brunsveld L; Scharnhorst V; van de Kerkhof D
J Pharm Biomed Anal; 2022 Nov; 221():115027. PubMed ID: 36099723
[TBL] [Abstract][Full Text] [Related]
60. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W.
Vreken P; Van Kuilenburg AB; Meinsma R; van Gennip AH
Hum Genet; 1997 Dec; 101(3):333-8. PubMed ID: 9439663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
